Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI)

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3331-3336

  De Jonge, B L M ^a   Kutschke, A ^a   Uria Nickelsen, M ^a   Kamp, H D ^a,b   Mills, S D ^a  

^a Infection Discovery   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; GLUTAMATE RACEMASE; PEPTIDOGLYCAN; PYRAZOLOPYRIMIDINEDIONE DERIVATIVE; RACEMASE; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG INHIBITION; DRUG STRUCTURE; HELICOBACTER PYLORI; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID ISOMERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME ACTIVATION; HELICOBACTER PYLORI; PEPTIDOGLYCAN; PYRIMIDINES;

EID: 67749095984     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00226-09     Document Type: Article

References (32)

1. Alm, R. A., J. Bina, B. M. Andrews, P. Doig, R. E. W. Hancock, and T. J. Trust. 2000. Comparative genomics of Helicobacter pylori: analysis of the outer membrane protein families. Infect. Immun. 68:4155-4168.
2. Alm, R. A., L. S. Ling, D. T. Moir, B. L. King, E. D. Brown, P. C. Doig, D. R. Smith, B. Noonan, B. C. Guild, B. L. de Jonge, G. Carmel, P. J. Tummino, A. Caruso, M. Uria-Nickelsen, D. M. Mills, C. Ives, R. Gibson, D. Merberg, S. D. Mills, Q. Jiang, D. E. Taylor, G. F. Vovis, and T. J. Trust. 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397:176-180.
3. Basarab, G. S., P. J. Hill, A. Rastagar, and P. J. H. Webborn. 2008. Design of Helicobacter pylori glutamate racemase inhibitors as selective antibacterial agents: a novel pro-drug approach to increase exposure. Bioorg. Med. Chem. Lett. 18:4716-4722.
4. Baum, E. Z., S. M. Crespo-Carbone, A. Klinger, B. D. Foleno, I. Turchi, M. Macielag, and K. Bush. 2007. A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli. Antimicrob. Agents Chemother. 51:4420-4426.
5. Bazzoli, F. 2001. Key points from the revised Maastricht Consensus Report: the impact on general practice. Eur. J. Gastroenterol. Hepatol 13(Suppl. 2):S3-S7.
6. Berry, V., K. Jennings, and G. Woodnutt. 1995. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob. Agents Chemother. 39:1859-1861.
7. Braun, V., H. Gnirke, U. Henning, and K. Rehn. 1973. Model of the structure of the shape-maintaining layer of the Escherichia coli cell envelope. J. Bacteriol. 114:1264-1270.
8. Chen, D. Z., D. V. Patel, C. J. Hackbarth, W. Wang, G. Dreyer, D. C. Young, P. S. Margolis, C. Wu, Z.-J. Ni, J. Trias, R. J. White, and Z. Yuan. 2000. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39:1256-1262.
9. Clinical and Laboratory Standards Institute. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 5th ed. CLSI document M11-A5. CLSI, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2003. Performance standards for antimicrobial susceptibility testing; 13th informational supplement. CLSI document M100-S13. CLSI, Wayne, PA.
11. de Jonge, B. L. M., A. Kutschke, M. Uria-Nickelsen, H. D. Kamp, and S. D. Mills. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1817.
12. Doublet, P., J. van Heijenoort, J.-P. Bohin, and D. Mengin-Lecreulx. 1993. The murI gene of Escherichia coli is an essential gene that encodes a glutamase racemase activity. J. Bacteriol. 175:2970-2979.
13. Fisher, S. L. 2008. Glutamate racemase as a target for drug discovery. Microb. Biotechnol. 1:345-360.
14. Flouret, B., D. Mengin-Lecreulx, and J. van Heijenoort. 1981. Reverse-phase high-pressure liquid chromatography of uridine diphosphate N-acetylmuramyl peptide precursors of bacterial cell wall peptidoglycan. Anal. Biochem. 114:59-63.
15. Grant, S. G., J. Jessee, F. R. Bloom, and D. Hanahan. 1990. Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc. Natl. Acad. Sci. USA 87:4645-4649.
16. Kostrzynska, M., J. D. Betts, J. W. Austin, and T. J. Trust. 1991. Identifi-cation, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella. J. Bacteriol. 173:937-946.
17. Kutschke, A., and B. L. M. de Jonge. 2005. Compound efflux in Helicobacter pylori. Antimicrob. Agents Chemother. 49:3009-3010.
18. Lundqvist, T., S. Fisher, G. Kern, R. H. A. Folmer, Y. Xue, D. T. Newton, T. A. Keating, R. A. Alm, and B. L. M. de Jonge. 2007. Exploitation of structural and regulatory diversity in glutamate racemases. Nature 447:817-822.
19. Mengin-Lecreulx, D., B. Flouret, and J. van Heijenoort. 1982. Cytoplasmic steps of peptidoglycan synthesis in Escherichia coli. J. Bacteriol. 151:1109-1117.
20. Payne, D. J., W. H. Miller, V. Berry, J. Brosky, W. J. Burgess, E. Chen, W. E. DeWolf, Jr., A. P. Fosberry, R. Greenwood, M. S. Head, D. A. Heerding, C. A. Janson, D. D. Jaworski, P. M. Keller, P. J. Manley, T. D. Moore, K. A. Newlander, S. Pearson, B. J. Polizzi, X. Qiu, S. F. Rittenhouse, C. Slater-Radosti, K. L. Salyers, M. A. Seefeld, M. G. Smyth, D. T. Takata, I. N. Uzinskas, K. Vaidya, N. G. Wallis, S. B. Winram, C. C. K. Yuan, and W. F. Huffman. 2002. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46:3118-3124.
21. Peek, R. M., and M. J. Blaser. 2002. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2:28-37.
22. Sambrook, J., E. F. Fritsch, and T. Maniatis. (ed.). 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
23. Sorberg, M., M. Nilsson, H. Hanberger, and L. E. Nilsoson. 1996., Morphological conversion of Helicobacter pylori from bacillary to coccoid form. Eur. J. Clin. Microbiol. Infect. Dis. 15:216-219.
24. Suerbaum, S., and P. Michetti. 2002. Medical progress: Helicobacter pylori infection. N. Engl. J. Med. 347:1175-1186.
25. Uemura, N., S. Okamoto, S. Yamamoto, N. Matsumura, S. Yamaguchi, M. Yamakido, K. Taniyama, N. Sasaki, and R. J. Schlemper. 2001. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345:784-789.
26. van Heijenoort, J. 2001. Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat. Prod. Rep. 18:503-519.
27. Wang, Y., K. P. Roos, and D. E. Taylor. 1993. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J. Gen. Microbiol. 139:2485-2493.
28. Wong B. C-Y., S. K. Lam, W. M. Wong, J. S. Chen, T. T. Zheng, R. E. Feng, K. C. Lai, W. H. C. Hu, S. T. Yuen, S. Y. Leung, D. Y. T. Fong, J. Ho, C. K. Ching, and J. S. Chen. 2004. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291:187-194.
29. Xu, N., Z. H. Huang, B. L. M. de Jonge, and D. Gage. 1997. Structural organization of peptidoglycan muropeptides by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and post-source decay analysis. Anal. Biochem. 248:7-14.
30. Yanisch-Perron, C., J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103-119.
31. Yao, R., R. A. Alm, T. J. Trust, and P. Guerry. 1993. Construction of new Campylobacter cloning vectors and a new mutational cat cassette. Gene 130:127-130.
32. Zhang, L., F. Fan, L. M. Palmer, M. A. Lonetto, C. Petit, L. L. Voelker, A. St. John, B. Bakosky, M. Rosenberg, and D. McDevitt. 2000. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 255:297-305.